Cargando…

Efficacy of Tetravalent Dengue Vaccine: A Systematic Review and Meta-Analysis

Dengue is one of the neglected tropical diseases caused by flavivirus. Live-attenuated tetravalent vaccine is launched for the age group of 9–45 years. It is given in three doses schedule. Eleven studies were included in meta-analysis by following PRISMA guidelines. Healthy persons in the age group...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khobragade, Ashish Wasudeo, Kadam, Dilip D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8281852/ https://www.ncbi.nlm.nih.gov/pubmed/34321724 http://dx.doi.org/10.4103/ijcm.IJCM_608_20

Ejemplares similares

Simulations to compare efficacies of tetravalent dengue vaccines and mosquito vector control
por: THAVARA, U., et al.
Publicado: (2014)

Clinical Efficacy, Safety, and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine (CYD-TDV) in Children: A Systematic Review with Meta-analysis
por: Malisheni, Moffat, et al.
Publicado: (2017)

Efficacy, immunogenicity and safety of a recombinant tetravalent dengue vaccine (CYD-TDV) in children aged 2–17 years: systematic review and meta-analysis
por: Rosa, Bruno Rodrigues, et al.
Publicado: (2019)

Genetic epidemiology of dengue viruses in phase III trials of the CYD tetravalent dengue vaccine and implications for efficacy
por: Rabaa, Maia A, et al.
Publicado: (2017)

Secondary Analysis of the Efficacy and Safety Trial Data of the Tetravalent Dengue Vaccine in Children and Adolescents in Colombia
por: Reynales, Humberto, et al.
Publicado: (2020)

Resource Use and Costs of Dengue: Analysis of Data from Phase III Efficacy Studies of a Tetravalent Dengue Vaccine
por: El Fezzazi, Hanna, et al.
Publicado: (2017)

Effect of the Tetravalent Dengue Vaccine TAK-003 on Sequential Episodes of Symptomatic Dengue
por: Sáez-Llorens, Xavier, et al.
Publicado: (2023)

Current Development and Challenges of Tetravalent Live-Attenuated Dengue Vaccines
por: Hou, Jue, et al.
Publicado: (2022)

Dengue seroprevalence: data from the clinical development of a tetravalent dengue vaccine in 14 countries (2005–2014)
por: L’Azou, Maïna, et al.
Publicado: (2018)

Immunogenicity and safety of a tetravalent dengue vaccine in dengue-naïve adolescents in Mexico City
por: Biswal, Shibadas, et al.
Publicado: (2021)

Design of Monovalent and Chimeric Tetravalent Dengue Vaccine Using an Immunoinformatics Approach
por: Dixit, Neeraj Kumar
Publicado: (2021)

Challenges to the Design of Clinical Trials for Live-Attenuated Tetravalent Dengue Vaccines
por: Russell, Philip K., et al.
Publicado: (2016)

Development of MVA-d34 Tetravalent Dengue Vaccine: Design and Immunogenicity
por: Mintaev, Ramil R., et al.
Publicado: (2023)

Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccination
por: Vigne, Claire, et al.
Publicado: (2017)

Spatial mapping and socio-demographic determinants of COVID-19 mortality in India
por: Khobragade, Ashish W., et al.
Publicado: (2021)

1051. Characterization of Immune Responses to a Live-Attenuated Tetravalent Dengue Vaccine
por: Braun, Ralph, et al.
Publicado: (2021)

Genetic and Phenotypic Characterization of Manufacturing Seeds for a Tetravalent Dengue Vaccine (DENVax)
por: Huang, Claire Y.-H., et al.
Publicado: (2013)

In silico prediction of monovalent and chimeric tetravalent vaccines for prevention and treatment of dengue fever
por: Subramaniyan, Vijayakumar, et al.
Publicado: (2018)

Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico
por: Dayan, Gustavo H, et al.
Publicado: (2014)

CYD Tetravalent Dengue Vaccine Performance by Baseline Immune Profile (Monotypic/Multitypic) in Dengue-Seropositive Individuals
por: DiazGranados, Carlos A, et al.
Publicado: (2020)

How India has managed the COVID-19 first and second waves?
por: Pal, Rahul, et al.
Publicado: (2022)

Specificity and Breadth of the Neutralizing Antibody Response to a Live-Attenuated Tetravalent Dengue Vaccine
por: DeMaso, Christina R, et al.
Publicado: (2022)

Preclinical proof of concept of a tetravalent lentiviral T-cell vaccine against dengue viruses
por: Nemirov, Kirill, et al.
Publicado: (2023)

Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties
por: Liu, Yan, et al.
Publicado: (2014)

Plant‐expressed Fc‐fusion protein tetravalent dengue vaccine with inherent adjuvant properties
por: Kim, Mi Young, et al.
Publicado: (2018)

Tetravalent dengue DNA vaccine is not immunogenic when delivered by retrograde infusion into salivary glands
por: El Helou, Guy, et al.
Publicado: (2020)

Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America
por: Forrat, Rémi, et al.
Publicado: (2021)

Neutralizing Antibody Response and Efficacy of Novel Recombinant Tetravalent Dengue DNA Vaccine Comprising Envelope Domain III in Mice
por: Kulkarni, Ajit, et al.
Publicado: (2017)

A tetravalent dengue nanoparticle stimulates antibody production in mice
por: Silva, Elisângela F, et al.
Publicado: (2012)

Induction of Neutralizing Antibodies against Four Serotypes of Dengue Viruses by MixBiEDIII, a Tetravalent Dengue Vaccine
por: Zhao, Hui, et al.
Publicado: (2014)

Development of a tetravalent subunit vaccine against dengue virus through a vaccinomics approach
por: Basheer, Amina, et al.
Publicado: (2023)

Virus-like particles with FLAG-tagged envelope protein as a tetravalent dengue vaccine candidate
por: Imagawa, Toshifumi, et al.
Publicado: (2021)

97. Tetravalent Dengue Vaccine (TAK-003) Development Program: A Bird’s Eye View
por: Tricou, Vianney, et al.
Publicado: (2021)

Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adults
por: LeFevre, Inge, et al.
Publicado: (2023)

Associations of human leukocyte antigen with neutralizing antibody titers in a tetravalent dengue vaccine phase 2 efficacy trial in Thailand
por: Thomas, Rasmi, et al.
Publicado: (2022)

Prevalence of Stress and Insomnia among Health Care Workers in India during COVID-19 Pandemic: A Systematic Review and Meta-analysis
por: Khobragade, Ashish W., et al.
Publicado: (2023)

A tetravalent live attenuated dengue virus vaccine stimulates balanced immunity to multiple serotypes in humans
por: Nivarthi, Usha K., et al.
Publicado: (2021)

Development of a Novel Assay to Assess the Avidity of Dengue Virus-Specific Antibodies Elicited in Response to a Tetravalent Dengue Vaccine
por: Tsuji, Isamu, et al.
Publicado: (2021)

A case-control study to determine the effectiveness of a tetravalent dengue vaccine in the state of Paraná, Brazil
por: de Moraes, José Cássio, et al.
Publicado: (2021)

Long-term protection against dengue viruses in mice conferred by a tetravalent DNA vaccine candidate
por: Wang, Ran, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_sjb8vdpuvveul7j00hi6bh7m13